Skip to content


Media Release

Kinoxis Therapeutics

Melbourne, Australia, 8 June 2023

Kinoxis awarded new US grant funding to support clinical development of KNX100 for opioid use disorder.

Melbourne, Australia, 5 May 2023

Kinoxis Therapeutics partners with Boehringer Ingelheim to develop novel treatments for psychiatric patients with social dysfunction symptoms.

Melbourne, Australia, 22 December 2020

Kinoxis Completes $5M Financing Round and Advances Lead Program Through Key Toxicology Studies

Melbourne, Australia, 30 September 2019

Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal

Melbourne, Australia, 15 February 2018

Kinoxis Therapeutics Launched to Develop Novel Anti-addiction Drugs

Follow us on social media

stay up to date with the latest in Kinoxis research & news